Use of diagnostic tests and procedures for disease-modifying therapy users and non-disease-modifying therapy users with multiple sclerosis

References

• Bainbridge J, Corboy JR. Multiple sclerosis. In: Pharmacotherapy: A Pathophysiologic Approach (7th Edition). DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds). The McGraw-Hill Companies (Medical), NY, USA, 913–926 (2007).
   Google Scholar
• Rizvi SA, Aguis MA. Current approved options for treating patients with MS. Neurology63, S8–S14 (2004).
   Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol.50, 121–127 (2001).
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann. Neurol.58, 840–846 (2005).
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohmam EN, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report to the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology58, 169–178 (2002).
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA et al. Extended use of glatiramer acetate is well tolerated and maintains its clinical effect on MS relapse rate and degree of stability. Neurology50, 701–708 (1998).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Gonsetee R, Koenig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360, 2018–2025 (2002).
   PubMed Web of Science ®Google Scholar
• Caon C, Saunders C, Smrtka J, Baxter N, Shoemaker J. Injectable disease-modifying therapy for relapsing-remitting multiple sclerosis: a review of adherence data. J. Neurosci. Nurs.42, S5–S9 (2010).
   PubMed Web of Science ®Google Scholar
• Lipsy RJ. Will the newer oral MS agents be welcomed by managed care organizations? Am. J. Manag. Care16, S227–S233 (2010).
   PubMedGoogle Scholar
• Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence4, 1–9 (2010).
   PubMed Web of Science ®Google Scholar
• Lugaresi A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation? Expert Opin. Drug Deliv.6, 995–1002 (2009).
   PubMed Web of Science ®Google Scholar
• Rio J, Porcel J, Téllez N et al. Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult. Scler.11, 306–309 (2005).
   PubMed Web of Science ®Google Scholar
• Costello K, Kennedy P, Scanzillo J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J. Med.10, 225 (2008).
   PubMedGoogle Scholar
• Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J. Neurosci. Nurs.42, S10–S18 (2010).
   Google Scholar
• Thannhauser JE, Mah JK, Metz LM. Adherence of adolescents to multiple sclerosis disease-modifying therapy. Pediatr. Neurol.41, 119–123 (2009).
   PubMed Web of Science ®Google Scholar
• Bruce JM, Hancock LM, Arnett P, Lynch S. Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J. Behav. Med.33, 219–227 (2010).
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Effect of physical comorbidities on risk of depression in multiple sclerosis. Int. J. MS Care11, 161–165 (2009).
   Google Scholar
• Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult. Scler.7, 340–344 (2001).
   PubMed Web of Science ®Google Scholar
• Devitt M, Foley FW, Miller RJ. Use of single screening question from NARCOMS to detect severe depression in multiple sclerosis. Int. J. MS Care10, 11–13 (2008).
   Google Scholar
• Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9 CM administrative databases. J. Clin. Epidemiol.45, 613–619 (1992).
   PubMed Web of Science ®Google Scholar
• Mullen JT, Vartanian TK, Atkins MB. Melanoma complicating treatment with natalizumab for multiple sclerosis. N. Engl. J. Med.358, 647–648 (2008).
   PubMed Web of Science ®Google Scholar
• Paul F, Dörr J, Würfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Neurol. Neurosurg. Psychiatry78, 198–200 (2007).
   PubMed Web of Science ®Google Scholar
• Monge-Argilés JA, Palacios-Ortega F, Vila-Sobrino JA, Matias-Guiu J. Heart rate variability in multiple sclerosis during a stable phase. Acta Neurol. Scand.97, 86–92 (1998).
   PubMedGoogle Scholar
• Walther EU, Hohlfeld R. Multiple sclerosis: side effects of interferon β therapy and their management. Neurology53, 1622–1627 (1999).
   PubMed Web of Science ®Google Scholar
• Caraccio N, Dardano A, Manfredonia F et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferonβ 1a or 1b therapy: predictive factors of thyroid disease development and duration. J. Clin. Endocrinol. Metab.90, 4133–4137 (2005).
   PubMed Web of Science ®Google Scholar
• Lovrecic L, Ristic S, Starcevic-Cizmarevic N et al. Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. Acta Neurol. Scand.114, 374–377 (2006).
   PubMedGoogle Scholar
• Vrethem M, Mattsson E, Hebelka H et al. Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acid. Mult. Scler.9, 239–245 (2003).
   PubMed Web of Science ®Google Scholar
• Calabresi P. Multiple sclerosis and demyelinating conditions of the central nervous system. In: Cecil Medicine (23rd Edition). Goldman L, Ausiello D (Eds). Saunders Elsevier, PA, USA Chapter 436 (2007).
   Google Scholar
• Altintas A, Demir T, Ikitimur H, Yildirim N. Pulmonary function in multiple sclerosis without any respiratory complaints. Clin. Neurol. Neurosurg.109, 242–246 (2007).
   PubMed Web of Science ®Google Scholar